NCT01009775 - A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

August 31, 2012

Conditions

Melanoma

Interventions

DRUG

YM155

intravenous infusion

DRUG

Docetaxel

intravenous infusion

Trial Locations (13)

St. Lukes Hospital Cancer Center, Bethlehem

H. Lee Moffitt Cancer Center, Tampa

University of South Alabama, Mobile

Univ. of Michigan Health System, Ann Arbor

MD Anderson Cancer Center, Houston

University of Colorado, Aurora

Arizona Clinical Research Center, Tuscon

The Angeles Clinic and Research, Los Angeles

UCLA, Los Angeles

Redwood Regional Medical Group, Sebastopol

University of South Alabama, Mobile

Univ. of Michigan Health System, Ann Arbor

London Regional Cancer Centre, London